Welcome to our newsroom.
The Emmes Corporation launched its new presence in Frederick County, Maryland, holding a ribbon-cutting event for local officials, employees and business partners on June 28. Dr. Anne Lindblad, president and CEO, said, “One benefit of opening an office in Frederick was to allow our headquarters staff to work closer to home and reduce their commuting time. Employees were given the choice of remaining at the Rockville headquarters, moving to the new Frederick office, or splitting their time between the two locations.” More than 50 Emmes employees opted to work full- or part-time in the Frederick office. The company, which has been ranked as the area’s fifth largest bioscience employer, is now recruiting to fill 28 positions in anticipation of additional growth at this location.
The Emmes Corporation today announced that it has expanded its operations in greater Washington to include a new office in Frederick, Maryland. The company now has five offices: two in Maryland, one in Canada and two in India. "Opening a new office during our 40th anniversary year is especially gratifying," said Dr. Anne Lindblad, president and chief executive officer of Emmes. "Our reputation in clinical research attracts great people, and that’s a key reason for our expansion."
The Emmes Corporation today announced that it was selected as one of the best places to work in the greater Washington area. The Washington Post’s 2017 Top Workplaces list ranked private, public, nonprofit and government agencies based on the highest engagement ratings from their employees. The Washington Post used Workplace Dynamics to conduct the survey, with 3,000 area companies invited to participate and 150 organizations selected as Top Workplaces. Emmes was ranked 15th out of 25 in the large company category and was one of only two biotechnology organizations to make the list.
The Emmes Corporation today announced that Dr. Paul VanVeldhuisen, chief operating officer and principal investigator, co-authored a study published by the Journal of the American Medical Association (JAMA). The study focused on the efficacy and safety of a commonly used, off-label drug called Avastin in treating macular edema due to central retinal vein occlusion. The study also addressed how Avastin compared to another drug, Eylea, which has been approved by the FDA and is being used to treat the same disease. The 2-1/2-year study with nearly 400 patients concluded that Avastin was as effective as Eylea in improving vision after six months of treatment. The cost of Avastin is $60 per dose compared to Eylea’s $1,850 per dose.
The Emmes Corporation today announced a contract spanning just over four years for a Phase 2 study of a Zika vaccine. The contract, valued at up to $27.6 million, expands the initial Phase 1 testing that began last year. This is the first-ever Phase 2 study for a Zika vaccine. Dr. Anne Lindblad, president and chief executive officer of Emmes, said, “The win is important because it expands our role in combating the Zika virus, a significant and enduring public health challenge.”